| abstract |
The present invention relates to an amorphous, lyophilized parenteral preparation of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno [2,3-b] [1,5] benzodiazepine, also known as olanzapine, containing from 1 mg / ml to about 20 mg / ml olanzapine, from about 22.5 mg / ml to about 50 mg / ml lactose monohydrate and from about 0.35 mg / ml to about 10 mg / ml tartaric acid . The invention also relates to a process for the preparation of the composition and to the use of the composition for the treatment of agitation. SHE |